Century Therapeutics Clinical Trial Data
Century Therapeutics presented updated nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026 meeting. The data demonstrated sustained glycemic control in diabetic mouse models for over eleven months and confirmed manufacturing consistency across five clinical-scale batches. The company remains on track to submit an IND for CNTY-813 in Q4 2026, with initial clinical data expected in the second half of 2027.
- Counterparty
- European Association for the Study of Diabetes (EASD)